Table 1.
Biomarkers identified in circulating EVs in osteosarcoma.
| Biomarker | Sample Type | Number of patients analyzed | References |
|---|---|---|---|
| EV-associated TGFβ | Human serum |
n = 10 OS patients n = 10 healthy donors |
(24) |
| EV-associated SERPING1, HEL-S-71p, HBB, KRT10, HEL180, TIH1, IGLC7, DC33, and characterized protein | Canine serum |
n = 8 OS group n = 5 healthy dogs with traumatic bone fractures n = 5 healthy, size-matched controls |
(68) |
| EV-associated SERPIND1 and class III MHC | Canine serum |
n = 5 OS diagnosis n = 5, 2 weeks after amputation n = 5 onset of lung metastases |
(68) |
| Serum exosomal miRNAs: miR-124, miR133a, miR-9, miR199a-3p, miR-385, miR-135b, miR-148a, miR-27a Serum exosomal mRNAs: Annexin2, Smad2, MTAP, CIP4, PEDF, WWOX, Cdc5L, P27 |
Human serum |
n = 48 OS patients with poor chemotherapeutic n = 45 OS patients with good chemotherapeutic response n = 51 healthy donors |
(69) |
| EVRNA carries aberrant gene fusions | Human plasma |
n = 3 OS presurgery patients n = 3 OS metastatic patients |
(70) |
| Mutations of RNA in circulating EVs | Human blood |
n = 40 metastatic and non-metastatic patients Recruiting is still ongoing. |
ClinicalTrials.gov Identifier: NCT03108677 |